Share Price:

APNASPENAspen Pharmacare Hldgs14500-149 (-1.02%)
Our Response to Covid
Country Sites

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Author: Shauneen Beukes

Aspen, Saudi Chemical Company Holding and its subsidiary AJA Pharma enter into a memorandum of understanding.

Dubai, United Arab Emirates – Aspen Healthcare FZ LLC (“Aspen Healthcare”), a subsidiary of Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded multinational pharmaceutical company, has entered into a memorandum of understanding (“MOU”) with Saudi Chemical Company Holding (“SCCH”), a well-known company in the local market of the Kingdom of Saudi Arabia, and its subsidiary AJA Pharmaceutical Industries Ltd (“AJA Pharma”), a recognized manufacturer of pharmaceutical products. In terms of this MOU, Aspen, SCCH and AJA Pharma will further expand their existing partnership to strategically collaborate on an extended portfolio of products, the manufacturing of products in the Kingdom of Saudi Arabia, and the export of products to existing Aspen markets.  Daniel Vella Friggieri, Aspen Healthcare Regional CEO for Middle East, North Africa & Turkey, said, “We are excited to announce our strategic collaboration with Saudi Chemical Company Holding and its subsidiary AJA Pharma. This agreement endorses Aspen’s continuous commitment to align with the Kingdom’s 2030 vision and our drive to provide high quality healthcare products to patients in the Kingdom, the Middle East region and beyond”. Thamer Almuhid, Saudi Chemical Company Holding Group CEO commented, “Nowadays technology and globalization play a more important role than ever; having a strategic partnership between Aspen and AJA Pharma will ensure that both the aspects of technologies and global market access are fulfilled towards achieving the KSA 2030 vision. We are pleased to partner with a trusted partner like Aspen and look forward to a prosperous strategic partnership”.

Aspen reports a creditable and resilient performance under challenging trading conditions

Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported creditable unaudited interim Group financial results for the six months ended 31 December 2022.   Salient Highlights   Revenue decreased by 1% (-6% in constant exchange rate (“CER”)) to R19,2 billion (December 2021: R19,4 billion) Normalised EBITDA decreased by 11% (-15% in CER) to R5,1 billion (December 2021: R5,7 billion) Normalised headline earnings per share decreased by 17% (-21% in CER) to 679.6 cents (December 2021: 816.4 cents) Headline earnings per share decreased by 15% (-20% in CER) to 660.6 cents (December 2021: 777.2 cents) Earnings per share decreased by 18% (-23% in CER) to 602.0 cents (December 2021: 736.2 cents) Improved Commercial Pharma gross profit margins helped deflect inflationary headwinds Significant advances have been made in contract negotiations with multinational customers seeking to secure a portion of Aspen’s sterile manufacturing capacities The technical transfer project for manufacture of the finished dose form vaccines licensed from Serum Institute of India is well advanced   Stephen Saad, Aspen Group Chief Executive said, “The Group’s performance under challenging trading conditions was anticipated and is aligned to guidance previously shared for the first half of the financial year. Consistent with our previous communications, we are optimistic that the results for the second half of this financial year will not only exceed those reported for the first half but will also exceed those of the second half of the prior year. We are pleased to report that we are at advanced stages of contract negotiations to fill a portion of  the additional sterile manufacturing capacities we have developed. Once concluded, this new manufacturing business is anticipated to realise a contribution of R2 billion in the 2024 calendar year, increasing to R4 billion in calendar year 2025. During the second half of this financial year we also anticipate closing important product portfolio transactions which will further enhance the Commercial Pharmaceuticals businesses in Latin America and South Africa.”   GROUP HIGHLIGHTS   Key Financial Indicators1 GROUP PERFORMANCE   The Group has delivered a creditable and resilient performance under challenging trading conditions. As previously guided, relative to the prior comparative period, this half was impacted by the Russian/Ukraine war, inflationary pressure, COVID lockdowns and volume-based procurement impacts in China as well as the loss of COVID vaccine sales. These headwinds had some offsets from improved margins in Commercial Pharmaceuticals.   Group revenue for the six months ended 31 December 2022 declined by 1% (-6% CER) to R19 150 million with Commercial Pharmaceuticals revenue growing 2% (-4% CER). Manufacturing revenue declined by 10% (-12% CER). Gross profit fell by 5% (-9% CER) as the reduction in Manufacturing gross profit margins from lost COVID vaccine contributions more than offset the improvement in Commercial Pharmaceuticals gross profit margins. Normalised EBITDA recorded negative growth of 11% (-15% CER) at R5 083 million. Lower net interest costs partly mitigated the increase in net financing costs arising from net foreign exchange losses of R234 million following the weakening of emerging market currencies. NHEPS declined by 17% (-21% CER) to 679,6 cents.   The Group’s leverage ratio remained comfortably below target levels with reported net borrowings of R18,8 billion.  During this period of uncertainty, given the war in Ukraine and COVID related supply impacts, there was increased investment in inventory by the Manufacturing segment. We have sufficient confidence to substantially unwind this working capital investment in the second half of the financial year.   Aspen successfully concluded agreements with each of the Bill & Melinda Gates Foundation (“the Gates Foundation”) and the Coalition for Epidemic Preparedness Innovations (“CEPI”) to support African regional manufacturing capacity for an affordable supply of vaccines.   Important advances were also made in the negotiation of key manufacturing contracts.   SEGMENTAL PERFORMANCE (AT CER) Commercial Pharmaceuticals   Commercial Pharmaceuticals revenue, comprising Regional Brands and Sterile Focus Brands, declined by 4% to R14 547 million. Revenue was negatively impacted, primarily by the divestment of certain products in South Africa in March 2022 as well as by the challenges documented earlier. The improved gross profit margin percentage resulted in a lower decline in gross profit of 2% to R8 728 million.   Regional Brands   Revenue from our largest segment, Regional Brands, increased by 2% to R9 355 million with 7% growth from each of Australasia and the Americas being the major contributors. Excluding the impact of the product divestment in South Africa (R294 million), Regional Brands revenue grew 6% with growth in Africa Middle East of 5% on a comparable product basis.   Gross profit percentage was up at 59,7% (H1 2022: 57,0%), driven by cost of goods savings and favourable sales mix.   Sterile Focus Brands   Revenue from Sterile Focus Brands decreased by 13% to R5 192 million due to the aforementioned challenges in both Russia and China.   Although the gross profit percentage of 60,5% was lower than the prior year comparable period (H1 2022: 61,4%), it is an improved margin compared to the second half of the previous financial year (H2 2022: 59,0%). The cost of goods savings from insourcing production has more than offset higher inflationary and logistic cost pressures.   Manufacturing   Manufacturing revenue decreased by 12% to R4 603 million attributable to the lower COVID vaccine sales. Heparin revenue was impacted by the prioritisation of technical transfer work related to new customers offset by increased pricing to counter the rising cost of raw heparin.   The Manufacturing business has a high fixed cost base and consequently gains and losses of contribution are extremely impactful on profit margins. Gross profit margins were significantly lower at 5,2% (H1 2022: 19,2%), largely impacted by the loss of contribution from the manufacture of the COVID vaccine. This was exacerbated by revenue foregone to facilitate non-revenue generating technical transfer costs needed for the on-boarding of new sterile manufacturing opportunities. The receipt of the grant funding from the Gates Foundation and CEPI helped to partially offset sterile production costs related to the introduction of… Continue reading Aspen reports a creditable and resilient performance under challenging trading conditions

Aspen donates life-saving emergency relief to patients in Turkey and Syria

Johannesburg – Aspen, a leading global specialty and branded multinational pharmaceutical company, has positively responded to humanitarian calls for relief following the devastating 7.8 magnitude earthquake, along with a series of strong tremors and aftershocks, that tore through southeast Turkey and northwest Syria on 6 February 2023.   Stavros Nicolaou, Aspen Group Senior Executive Strategic Trade Development said, “Aspen has a reputation of responding to regional pandemics and humanitarian crises, both in our country and internationally. This is consistent with our core business philosophies of building sustainable communities where we have a presence and providing humanitarian relief to communities impacted by catastrophic events. The earthquakes experienced in both Syria and Turkey have devastated families and communities and inflicted significant human suffering. At these times we need to demonstrate a spirit of Ubuntu and stand in solidarity with vulnerable societies as we have done in the past. Aspen has responded by donating humanitarian relief in the form of critical care medicines which are used in emergency surgeries as well as thousands of blankets to ward off freezing conditions that are leading to patients contracting infections and becoming severely ill from hypothermic complications.”   Her Excellency Ms Aysegul Kandas, Turkish Ambassador to South Africa, said, “On behalf of the government and people of Türkiye, I express my heartfelt appreciation for the outpouring of support and generosity from Aspen Pharmacare and the people of South Africa in response to the recent disaster that has befallen our country. Your donations of medicines, blankets, and other humanitarian relief items will provide much-needed aid to those affected by this tragedy. Your kindness and compassion have given us hope during this difficult time and I hope that this action will inspire others to join us in our efforts to help those in need.  I believe that efforts like these will further strengthen the friendly ties between the peoples of Türkiye and South Africa.” Aspen confirmed that the critical care medicines and blankets are on route to Turkey and are expected to arrive in that country in due course. Aspen has a strong business presence in the Middle East and also distributes a range of pharmaceutical products in this territory.    Aspen has engaged in similar relief efforts by donating life-saving medicines to treat 62 000 patients in the Ukraine and also repatriating 25 South African students who were stranded in that country at the onset of the war. It also donated thousands of medicines to Lebanon during the gas explosion that decimated parts of Beirut. Domestically, Aspen significantly contributed to restoring medical services in KwaZulu-Natal (“KZN”) following the rioting and looting that took place in that province in July 2021, and it has provided relief to victims of flooding in KZN where communities were devastated by natural disasters.

Tragic passing of Riaan Verster (46)

Durban, South Africa – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), regrets to announce the untimely and tragic passing of Riaan Verster, Aspen Group Executive: Governance & Communications, on Saturday 28 January 2023. Riaan regrettably succumbed to his injuries sustained in a motor cycle accident.   Stephen Saad, Aspen Group Chief Executive, said, “Riaan was a dear friend to many, a valued leader, colleague and mentor and he demonstrated unwavering commitment to Aspen and the Group’s values which he proudly endorsed at every opportunity. He made a substantial impact on those who he dealt with professionally and personally and he always fulfilled his responsibilities with passion, excellence and commitment.”   Riaan joined Aspen on 1 December 2011 as Company Secretary and Group Governance Officer and he was subsequently appointed to the position of Group Executive: Governance & Communications. He also held the position of Company Secretary at the time of his passing. A further announcement regarding the appointment of an interim Company Secretary will be made in due course.   Riaan also actively campaigned for improved service and delivery on behalf of the community in which he lived with his family. He is survived by his wife Natelie, their daughter Jeanné and son Nathan.  

Aspen, CEPI and the Bill & Melinda Gates Foundation expand commitments to improve access to vaccines in Africa

Stephen Saad, Aspen Group Chief Executive

New funding supports technology transfer from Serum Institute to Aspen to manufacture routine vaccines in Africa, for Africa Collaboration supports sustainable manufacturing capacity for African-produced vaccines for future epidemics and pandemics   Durban, South Africa – JSE Limited listed Aspen Pharmacare Holdings Limited (“Aspen”) a global multinational specialty pharmaceutical company,  announced that it will receive USD30 million from the Bill & Melinda Gates Foundation (”the Gates Foundation”) and the Coalition for Epidemic Preparedness Innovations (“CEPI”) to support its capabilities to manufacture lifesaving routine and outbreak vaccines for Africa. The new funding from CEPI and the Gates Foundation, which includes USD15 million from each organization, will support a ten-year agreement between Aspen and Serum Institute of India Pvt Ltd (“Serum Institute”) that aims to expand the supply and sourcing of affordable vaccines manufactured in Africa. Through the partnership with Serum Institute, Aspen will manufacture and distribute four routine vaccines in Africa — Pneumococcal, Rotavirus, Polyvalent Meningococcal, and Hexavalent — with technology transfer activities initiating in early 2023. In addition to supporting the technology transfer of these routine vaccines, the funding from CEPI and the Gates Foundation will help sustain regional vaccine manufacturing capacity at Aspen for potential future outbreak response, with the intention of securing early access to African-produced vaccines in the event of a future public health emergency.   Stephen Saad, Aspen Group Chief Executive, said, “We thank both CEPI and the Gates Foundation for their commitment to support regional manufacture for Africa.  Their commitment, together with our partnership with Serum, is an important first step in ensuring expanded and enduring equitable access to a pipeline of medicines and vaccines manufactured in Africa for Africans. Aspen has a proven capability of being at the forefront of pandemic preparedness for the Continent – from ARVs to COVID vaccines. This support will ensure we can continue to invest and expand our capacities, secure in the knowledge of future offtakes.”   Dr Ahmed Ogwell Ouma, Acting Director Africa CDC said, “Africa CDC welcomes and wishes to congratulate Aspen, the Gates Foundation and CEPI on the conclusion of their respective agreements. These landmark agreements are a demonstration of Africa’s, and in this instance, Aspen’s ambition to further enhance Africa’s vaccine localisation efforts, its intention to diversify the pipeline for Africa-specific vaccines and to improve Africa’s ability to respond to pandemic outbreaks.  All these are critical elements to establishing health security and security of supply on the African continent in line with the vision of our New Public Health Order.”   “The urgent need to diversify vaccine manufacturing so every region can manage its own health security is one of the most significant learnings from the inequity of the COVID-19 pandemic response,” said Dr Richard Hatchett, CEO of CEPI. “CEPI is working with our partners at Africa CDC  to support the expansion of vaccine manufacturing on the continent, and our collaboration with Aspen, the Gates Foundation and Serum Institute will help to deliver a sustainable and resilient business model capable of both producing routine and outbreak vaccines in Africa, for Africa .”   “Expanding the availability of affordable, high-quality vaccines that meet the needs of local communities is one of the best ways to improve health outcomes and reduce preventable deaths,” said Mark Suzman, Chief Executive Officer of the Bill & Melinda Gates Foundation. “We’re very pleased to support this agreement between Aspen and Serum Institute, which has the potential to expand vaccine production and supply in Africa, increase vaccination rates, improve pandemic preparedness, and broadly strengthen global health security.”   Over the past two decades, the increased globalization of vaccine manufacturing has generated more reliable vaccine supplies at a lower cost, helping many countries around the world reach more people with lifesaving vaccines.  In Africa, however, 99% of all vaccines administered are currently imported. Because lifesaving vaccines and treatments are not available or affordable everywhere, vaccine-preventable diseases continue to have a devastating impact on the region.  Last year, African leaders, civil society, the private sector, and organizations such as the African Union and the Africa Centres for Disease Control laid out a vision to expand regional manufacturing capacity, including an ambitious plan to produce 60% of the continent’s vaccines locally by 2040 and the launch of the Partnership for African Vaccine Manufacturing (“PAVM”), as well as a call for supranational funders and procurement agencies to source at least 30% of their requirements from African manufacturers.                                    

Aspen closes EUR 1,26 billion syndicated loan facilities

Durban, South Africa – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has closed a multi-currency, syndicated term loan and revolving credit facilities agreement. These facilities, totalling circa EUR 1,26 billion equivalent, were put in place to refinance Aspen’s 2018 syndicated loan facilities.    The facilities were structured across EUR, ZAR and AUD term and revolving credit facilities, with tenors of three to four years and additional extension options available. All facilities were consolidated into a single facility agreement, with lenders ranking pari-passu. Following primary syndication, the transaction was significantly oversubscribed thereby providing substantial scale-back to the lenders.   Stephen Saad, Aspen Group Chief Executive said, “We are very pleased with the outcome of this syndication particularly noting the current global risk-off sentiment. It is encouraging to see that all invited lenders have supported the transaction which is testament to their confidence in the Aspen Group.”   Citi, FirstRand Bank Limited, acting through its Rand Merchant Bank division (“RMB”), MUFG Bank (Europe) N.V. (“MUFG”), and Nedbank Limited, acting through its Nedbank Corporate and Investment Banking division (“Nedbank”) acted as Coordinators, Bookrunners and Initial Mandated Lead Arrangers for this transaction. MUFG acted as the Documentation Agent while ABSA Bank Limited acted as Facility Agent and RMB as the Publicity Agent.    Coordinators, Initial Mandated Lead Arrangers and Bookrunners:   Mandated Lead Arrangers:   Lead Arrangers:

Aspen delivers double digit organic growth in normalised EBITDA, operating profit and earnings

Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, is pleased to report reviewed provisional Group financial results for the year ended 30 June 2022.   SALIENT FEATURES Revenue from continuing operations increased by 2% (+5% in constant exchange rate (“CER”)) to R38,6 billion (FY2021: R37,8 billion); Normalised EBITDA from continuing operations increased by 11% (+13% in CER) to R11,0 billion (FY2021: R9,9 billion); Normalised headline earnings per share from continuing operations increased by 24% (+26% in CER) to 1 627,6 cents (FY2021: 1 309,7 cents); Headline earnings per share from total operations increased by 31% (+31% in CER) to 1 461,2 cents (FY2021: 1 119,1 cents); Earnings per share from total operations increased by 36% (+36% in CER) to 1 432,3 cents (FY2021: 1 052,9 cents); Dividend declared to shareholders increased by 24% to 326 cents per ordinary share (FY2021: 262 cents); Aspen signs 10-year agreement with the world’s largest vaccine producer, Serum Institute of India.   Stephen Saad, Aspen Group Chief Executive said, “The Group has achieved a robust set of results for the year ended 30 June 2022, supported by improved operating margins underpinned by a lower operating expense base and a strong balance sheet, all of which provide a solid foundation for future sustainable growth.”   “Aspen has concluded a 10-year collaboration agreement with Serum Institute of India Pvt. Ltd. (“the Serum Institute”) to manufacture, market and distribute four Aspen-branded routine vaccines in Africa. In responding to the COVID-19 pandemic, investing billions to establish world class steriles manufacturing capability, Aspen has demonstrated its ability to partner successfully to deliver millions of doses of vaccine to the highest standard. Through this agreement with the Serum Institute, the partners are responding to the African Union’s call for more African vaccine manufacturing on the continent. Enhancing access to medicines is at the forefront of Aspen’s ESG strategy. ”   GROUP HIGHLIGHTS (CONTINUING OPERATIONS) 1 – The Group assesses its operational performance using constant exchange rate (“CER”) and all segmental performance-related commentary is made with reference to the underlying CER trends. The table above compares performance from continuing operations to the prior comparable period at reported exchange rates and at CER. 2 – The CER % change is based upon the performance for the year ended 30 June 2021 restated using the average exchange rates for the year ended 30 June 2022. 3 – Operating profit before depreciation and amortisation adjusted for specific non-trading items as set out in the normalised headline earnings reconciliation on page 8 of Aspen’s Year End Results Booklet available at www.aspenpharma.com. 4 – Normalised headline earnings per share (“NHEPS”) represents headlines earnings per share (“HEPS”) adjusted for specific non-trading items as defined in the Group’s accounting policy. 5 – Dividend declared on 31 August 2022, to be paid on 26 September 2022 (2021: Declared on 1 September and paid 27 September 2021). GROUP PERFORMANCE (CONTINUING OPERATIONS) The Group has delivered a strong performance, with double digit organic growth in normalised EBITDA, operating profit and earnings. This performance is testimony to Aspen’s resilience against the backdrop of a challenging trading environment and inflationary cost pressures.   Group revenue for the financial year ended 30 June 2022 grew 2% (+5% CER) to R38 606 million with Commercial Pharmaceuticals revenue declining 1% (+1% CER) and Manufacturing revenue increasing 11% (+18% CER). Gross profit growth of 3% (+5% CER) slightly exceeded revenue growth, with the underlying segmental gross margins all showing improvement. The increased contribution from the lower margin Manufacturing segment diluted the overall gross margin percentage. Normalised EBITDA rose 11% (+13% CER) to R11 012 million, largely due to the leverage provided by lower operating expenses. NHEPS increased 24% (+26% CER) to 1627.6 cents, bolstered by reduced net financing costs. The higher percentage growth in earnings per share, relative to HEPS, is attributable to the profit on the sale of a product portfolio divested in South Africa.   Net borrowings reduced to R16,1 billion, down from the R16,3 billion reported at 30 June 2021, ensuring that the Group’s leverage ratio remained comfortably below target levels. This provided the Group with an opportunity to fund a share buy-back of R1,8 billion (2.2% of issued shares) during the year. Operating cash flow was impacted as a consequence of increased inventory investment by the Manufacturing segment in key input materials to mitigate future supply constraint risks which may arise from continued global supply chain disruptions.   SEGMENTAL PERFORMANCE (CONTINUING OPERATIONS AT CER) Commercial Pharmaceuticals Commercial Pharmaceuticals, comprising of Regional Brands and Sterile Focus Brands, grew 1% to R27 658 million. Solid underlying volume growth of 4% was impacted, primarily, by the divestment of certain products in South Africa, challenges faced by our Chinese business, including volume-based procurement (“VBP”) and COVID-19 (“COVID”) related lockdowns, as well as the impact of the geopolitical situation in Russia and Ukraine on our businesses there. Gross profit increased 3% to R16,1 billion, supported by improved margins in both Regional and Sterile Focus Brands, despite the inflationary and freight cost headwinds experienced, particularly in the second half of the financial year.   Regional Brands Regional Brands revenue increased by 3% to R17 405 million, with 13% growth from Australasia and 8% from the Americas, being the major contributors. Supply constraints and product portfolio divestments impacted the performance of Africa Middle East. Gross profit percentage was up at 56.5% (FY2021: 54.6%), driven by cost of goods savings and portfolio optimisation, combined with a favourable product mix.   Sterile Focus Brands Revenue from Sterile Focus Brands decreased 2% to R10 253 million due to lower sales in Russia CIS during the second half of the financial year and the aforementioned challenges in China. A higher gross profit percentage of 60.7% (FY2021: 60.0%) benefitted from cost of goods savings partially offset by higher logistics costs.   Manufacturing Manufacturing revenue increased 18% to R10 948 million with significant growth in finished dose form sales. This included R1,4 billion in revenue from the fill and finish… Continue reading Aspen delivers double digit organic growth in normalised EBITDA, operating profit and earnings

Aspen hosts more than 800 Mandela Day activities over 12 years

“Our purpose, To improve the health and quality of life of patients is closely aligned to the ethos of Mandela Day. This has been clearly demonstrated through our endeavours to provide citizens across the continent with vaccines which are manufactured in South Africa for Africa.”   Durban – JSE Limited listed Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded pharmaceutical company, has hosted more than 800 activities over 12 years in celebration of the annual Nelson Mandela International Day (“Mandela Day”). Stephen Saad, Aspen Group Chief Executive said, “Our purpose, To improve the health and quality of life of patients is closely aligned to the ethos of Mandela Day. This has been clearly demonstrated through our endeavours to provide citizens across the continent with vaccines which are manufactured in South Africa for Africa. Aspen has participated in Mandela Day since 2011 and we continue to endorse the campaign which this year calls on people across the world to “Do what you can, with what you have, where you are”.  Our employees have shown their humanitarian spirit celebrating Mandela Day globally in spite of the limitations imposed by the COVID-19 pandemic. They have stood firm and continued to reach out and make a difference in the lives of others, particularly during recent years when the world needed a touch of kindness the most.” “Through Mandela Day, we live our ethos of Healthcare. We Care as we work alongside an extensive range of beneficiaries across 6 continents,” added Saad. “These include abandoned, neglected, orphaned or abused babies, children and women; the elderly, hungry and homeless; individuals dealing with mental wellness challenges; students who are eager to be educated; those who are disabled; victims of the Ukrainian conflict; residents at social rehabilitation institutions; and healthcare facilities and their patients who are in dire need of support and equipment, among others.” The Nelson Mandela Foundation’s focus for 2022 is to promote community and home-based gardens, supporting fruit and indigenous tree planting, and creating awareness of the intersections between food security and climate change. Similarly, a number of Aspen’s activities include environmental efforts such as tree planting; garden maintenance, preservation and enhancement; repackaging, repurposing and distributing surplus food; recycling and fighting pollution. Aspen’s Mandela Day projects cover a wide spectrum of initiatives that include healthcare, nutrition, education, social enhancement and development, infrastructural improvements, animal wellbeing, preserving the environment, and providing employees with the opportunity to show kindness to citizens of all ages from all walks of life. Since initiating our annual Mandela Day Campaign in 2011, Aspen has impacted the lives of some 880 000 beneficiaries through more than 810 projects hosted across 40 countries.   Read more about Aspen’s Mandela Day activities at www.aspenmandeladay.com, follow us on FaceBook, Twitter or LinkedIn and engage on social media via #aspenmandeladay.

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below:

Human Capital
Legal

Supply Chain

Treasury
Ethics & Compliance
Risk & Sustainability
Digital Technology

Tax